So Ra Park

Title: Innovations by So Ra Park: Advancements in Antibody Therapeutics

Introduction

So Ra Park, an accomplished inventor from Chungcheongbuk-do, South Korea, has made significant contributions to the field of biopharmaceuticals. With a focus on enhancing the effectiveness of antibodies, her innovative work seeks to address critical challenges in cancer treatment.

Latest Patents

So Ra Park holds a notable patent for "Antibody Fc variants for increased blood half-life." This invention relates to a polypeptide that includes an Fc variant achieved by substituting parts of the amino acid sequence of the Fc domain of a human antibody with a different amino acid sequence. The patent highlights the versatility of the Fc variant, which can be employed in various antibodies and Fc-fusion constructs. Particularly, this invention is aimed at maximizing the in vivo half-life of therapeutic antibodies, rendering them more effective in targeting cancer cells and other specific antigens.

Career Highlights

Throughout her career, So Ra Park has worked with prominent institutions such as Kookmin University and the Osong Medical Innovation Foundation. Her research has garnered attention for its potential applications in therapeutic and diagnostic settings, as well as in laboratory reagents. Her contributions to understanding antibody functionality have positioned her as a key figure in the ongoing battle against cancer.

Collaborations

So Ra Park has collaborated with esteemed colleagues, including Sang Taek Jung and Sanghwan Ko. These partnerships have allowed her to expand her research capabilities and make impactful strides in the biotechnology sector. Together, they have worked on optimizing antibodies and Fc-fusion constructs that demonstrate improved efficacy in clinical applications.

Conclusion

The innovations of So Ra Park represent a significant advancement in the development of antibody therapeutics. Her patented work on Fc variants not only highlights her inventive spirit but also offers promising avenues for enhanced cancer treatments. As she continues her research and collaboration with top institutions, So Ra Park is likely to remain at the forefront of biopharmaceutical innovation, contributing to better health outcomes worldwide.